Literature DB >> 11125361

De novo muscle invasive bladder cancer: is there a change in trend?

A Vaidya1, M S Soloway, C Hawke, R Tiguert, F Civantos.   

Abstract

PURPOSE: We reviewed our radical cystectomy series to determine whether the majority of patients present with muscle invasive bladder cancer.
MATERIALS AND METHODS: The records of 184 radical cystectomies performed by 1 surgeon from 1992 to 1999 were reviewed, and all slides of presenting pathology were reviewed by 1 pathologist. The pathological stage of the tumor at presentation was noted in each case, and the number of muscle invasive tumors at presentation was compared to 2 earlier series.
RESULTS: Radical cystectomy was performed for muscle invasive transitional cell carcinoma of the bladder in 176 cases and for other histology in 8. There were 101 (57.3%) patients with muscle invasive cancer at presentation compared to 84% and 91% in the 2 earlier series, respectively, which was a statistically significant decrease (p <0. 0001) in the number of de novo muscle invasive bladder cancers. Women were more likely to be diagnosed with muscle invasion primarily than men (85.2% and 50.7%, respectively), and younger patients (younger than 50 years) were more likely to present with superficial bladder cancer compared to those older than 50 years who were more likely to present with de novo muscle invasive bladder cancer.
CONCLUSIONS: Analysis of our data supports the findings of the earlier series that the majority of patients present with muscle invasive bladder cancer. However, there is a significant decrease in the percentage of tumors invading the muscularis propria at presentation. Although this observation is encouraging, we emphasize that it is not as dramatic as the stage migration associated with prostate cancer, which may be largely attributed to the widespread use of prostate specific antigen for early detection. Therefore, we support the suggestion that therapeutic gains might follow from improved education regarding the signs and symptoms associated with bladder cancer, with enhanced focus on women and consideration of screening methods for those at high risk for bladder cancer.

Entities:  

Mesh:

Year:  2001        PMID: 11125361     DOI: 10.1097/00005392-200101000-00012

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  25 in total

1.  Radical cystectomy is the treatment of choice for invasive bladder cancer.

Authors:  Faysal A Yafi; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2009-10       Impact factor: 1.862

Review 2.  Bladder cancer: Active surveillance for low-grade Ta bladder tumours.

Authors:  Mark S Soloway
Journal:  Nat Rev Urol       Date:  2016-02-16       Impact factor: 14.432

3.  Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes?

Authors:  Ahmed F Kotb; Evan Kovac; Wassim Kassouf; Joe Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; David Bell; Darrel Drachenberg; Armen G Aprikian
Journal:  World J Urol       Date:  2012-12       Impact factor: 4.226

4.  The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy.

Authors:  Nobuki Furubayashi; Takahito Negishi; Takuya Yamashita; Shuhei Kusano; Kenichi Taguchi; Mototsugu Shimokawa; Motonobu Nakamura
Journal:  Mol Clin Oncol       Date:  2017-10-13

5.  Screening for bladder cancer: the best opportunity to reduce mortality.

Authors:  Yves Fradet
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

Review 6.  Role of oestrogen receptors in bladder cancer development.

Authors:  Iawen Hsu; Spencer Vitkus; Jun Da; Shuyuan Yeh
Journal:  Nat Rev Urol       Date:  2013-04-16       Impact factor: 14.432

7.  Perioperative search for circulating tumor cells in patients undergoing radical cystectomy for bladder cancer.

Authors:  A Karl; S Tritschler; S Hofmann; C G Stief; C Schindlbeck
Journal:  Eur J Med Res       Date:  2009-11-03       Impact factor: 2.175

8.  Ureterocutaneostomy: for whom and when?

Authors:  Zafer Kozacıoğlu; Tansu Değirmenci; Bülent Günlüsoy; Yasin Ceylan; Süleyman Minareci
Journal:  Turk J Urol       Date:  2013-09

9.  Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3.

Authors:  Tian Fang; Dan-Dan Liu; He-Ming Ning; Jing-Ya Sun; Xiao-Jing Huang; Yu Dong; Mei-Yu Geng; Shi-Feng Yun; Jun Yan; Rui-Min Huang
Journal:  Acta Pharmacol Sin       Date:  2018-05-16       Impact factor: 6.150

10.  Incidentally found prostate cancer and influence on overall survival after radical cystoprostatectomy.

Authors:  Algimantas Sruogis; Albertas Ulys; Giedre Smailyte; Zygimantas Kardelis; Arunas Kulboka; Giedre Anglickienė; Nerimantas Samalavicius; Marius Anglickis
Journal:  Prostate Cancer       Date:  2012-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.